ADDAX
Acid Deprived DiAldehyde FiXative
ADDAX Biosciences is an academic spin-off of the University of Turin, born after long time research activity of its founders on the fixation of pathological tissues. Our company goal is to replace the use of Formalin (a cancerogenic and toxic solution of Formaldehyde) as a fixative solution, while preserving optimal tissue fixation to guarantee correct diagnosis and therapy.
MORE INFORMATIONS
Write us to learn more about GAF.
We believe it is necessary to guarantee the highest standard of accuracy and reliability of the examinations carried out on biological samples, in order to preserve the health of the patients. At the same time, we also deem necessary to safeguard the health of the operators.
CEO & Founder
Giovanni Bussolati
Emeritus Professor of Pathology
Member of the Italian Lincei Academy of Science
R&D & Founder
Benedetta Bussolati
Associate Professor of Nephrology at the University of Turin
Collaborator
Jasna Metovic
Medical Doctor and PhD student in Biomedical Sciences and Oncology
Collaborator
Francesca Veneziani
Biomedical Laboratory Technician
Investor
Fabio Bellio
Purchasing & Supply Chain Manager at Ahlstrom Munksjo Italia
Financial Advisor
Sergio Traversa
PharmD, MBA, CEO of Relmada Therapeutics Inc.
Financial Advisor
Enrico Sorisio
Chartered accountant, business and tax consultant
Scientific Advisor
Anna Sapino
Professor of Pathology
Scientific Director, IRCC Candiolo Institute of Oncology
Scientific Advisor
Manfred Dietel
Professor of Pathology
Director of Institute of Pathology, University Hospital Charitè, Berlin
Scientific Advisor
Giorgio Stanta
Professor of Pathology at the University of Trieste
Collaboration with A.O.U. Città della Salute e della Scienza in Turin, for the “Glyoxal in Endoscopy” project.
Collaboration with the Zooprophylactic Institute in Turin for GAF’s use in the veterinary sector, especially concerning neurological pathology.
Collaboration with the Polytechnic of Turin and the University of Turin for use of acid-free glyoxal as a fixative for valve and vascular prostheses.
Our company has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement No 8157692.